Captopril

Captopril
Clinical data
Pronunciation	/ˈkæptəprɪl/
Trade names	Capoten, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682823
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	C09AA01 (WHO) ;
Legal status
Legal status	EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	70–75%
Metabolism	Liver
Elimination half-life	1.9 hours
Excretion	Kidney
Identifiers
	IUPAC name (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid;
CAS Number	62571-86-2 ;
PubChem CID	44093;
IUPHAR/BPS	5158;
DrugBank	DB01197 ;
ChemSpider	40130 ;
UNII	9G64RSX1XD;
KEGG	D00251 ;
ChEBI	CHEBI:3380 ;
ChEMBL	ChEMBL1560 ;
PDB ligand	X8Z (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID1037197 ;
ECHA InfoCard	100.057.806
Chemical and physical data
Formula	C9H15NO3S
Molar mass	217.28 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@H]1N(C(=O)[C@H](C)CS)CCC1;
	InChI InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 ; Key:FAKRSMQSSFJEIM-RQJHMYQMSA-N ;
	(verify)

Captopril, sold under the brand name Capoten among others, is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure. Captopril was the first oral ACE inhibitor found for the treatment of hypertension. It does not cause fatigue as associated with beta-blockers.

Captopril was patented in 1976 and approved for medical use in 1980.